Initial and evolutive features of 157 patients with DLBCL
| Feature . | n (%) . |
|---|---|
| Age | |
| median (range) | 65 (17-91) |
| ≤ 60 y | 65 (41%) |
| Sex | |
| Female | 80 (51%) |
| Male | 77 (49%) |
| Poor performance status (ECOG-PS> 1) | 66 (42%) |
| B-symptoms | 55 (35%) |
| Extranodal involvement | 63 (40%) |
| Bone marrow involvement | 46 (29%) |
| Ann Arbor stage III-IV | 94 (60%) |
| High serum LDH | 93 (59%) |
| High serum β2-m* | 64 (47%) |
| IPI | |
| Low risk | 47 (30%) |
| Low/intermediate risk | 35 (22%) |
| High/intermediate risk | 38 (25%) |
| High risk | 37 (23%) |
| Response to therapy | |
| CR | 119 (76%) |
| Partial response | 4 (2%) |
| Nonresponse/progression | 34 (22%) |
| Feature . | n (%) . |
|---|---|
| Age | |
| median (range) | 65 (17-91) |
| ≤ 60 y | 65 (41%) |
| Sex | |
| Female | 80 (51%) |
| Male | 77 (49%) |
| Poor performance status (ECOG-PS> 1) | 66 (42%) |
| B-symptoms | 55 (35%) |
| Extranodal involvement | 63 (40%) |
| Bone marrow involvement | 46 (29%) |
| Ann Arbor stage III-IV | 94 (60%) |
| High serum LDH | 93 (59%) |
| High serum β2-m* | 64 (47%) |
| IPI | |
| Low risk | 47 (30%) |
| Low/intermediate risk | 35 (22%) |
| High/intermediate risk | 38 (25%) |
| High risk | 37 (23%) |
| Response to therapy | |
| CR | 119 (76%) |
| Partial response | 4 (2%) |
| Nonresponse/progression | 34 (22%) |
β2m levels were available in 135 cases.
ECOG-PS indicates Eastern Cooperative Oncology Group performance status.